Last reviewed · How we verify
Ergocalciferol (Vitamin D)
Ergocalciferol is a form of vitamin D that is converted in the body to its active metabolite, which regulates calcium and phosphate absorption and homeostasis.
Ergocalciferol is a form of vitamin D that is converted in the body to its active metabolite, which regulates calcium and phosphate absorption and homeostasis. Used for Vitamin D deficiency, Hypocalcemia, Hypoparathyroidism.
At a glance
| Generic name | Ergocalciferol (Vitamin D) |
|---|---|
| Also known as | Drisdol |
| Sponsor | Barts & The London NHS Trust |
| Drug class | Vitamin D supplement |
| Target | Vitamin D receptor (VDR) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Nutritional deficiency |
| Phase | FDA-approved |
Mechanism of action
Ergocalciferol (vitamin D2) is a fat-soluble vitamin that is hydroxylated in the liver to 25-hydroxyvitamin D and then in the kidneys to the active form 1,25-dihydroxyvitamin D. The active metabolite binds to vitamin D receptors in the intestine, bone, and kidney to promote calcium absorption, maintain serum calcium and phosphate levels, and support bone mineralization and immune function.
Approved indications
- Vitamin D deficiency
- Hypocalcemia
- Hypoparathyroidism
- Osteomalacia
- Rickets
Common side effects
- Hypercalcemia
- Hypercalciuria
- Nausea
- Vomiting
- Constipation
- Weakness
Key clinical trials
- Frequency of Fibromyalgia Syndrome in Elderly Patients Aged 80 and Above and Its Relationship With Geriatric Parameters
- Immune Mechanisms of Vitamin D to Reduce Chronic Pain After Burn (PHASE2)
- Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease (PHASE2)
- High-Dose vs Standard Ergocalciferol for Vitamin D Normalization in Aggressive Non-Hodgkin Lymphoma (NA)
- Vitamin D Homeostasis in Sarcoidosis (PHASE4)
- Vitamin D Deficiency in Adults Following a Major Burn Injury (PHASE4)
- Vitamin D Supplementation on Reported Rates of Taxane-Induced Neuropathy (PHASE2)
- Relationship Between Serum Vitamin D and Atherosclerosis in Hemodialysis Patients
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ergocalciferol (Vitamin D) CI brief — competitive landscape report
- Ergocalciferol (Vitamin D) updates RSS · CI watch RSS
- Barts & The London NHS Trust portfolio CI